
Serum Institute seeks DCGI’s approval for Covishield as booster dose
PTI, Dec 2, 2021, 11:57 AM IST

Serum Institute of India has sought from India’s drug regulator approval for Covishield as a booster dose citing adequate stock of the vaccine in the country and a demand for a booster shot due to the emergence of new coronavirus variants, official sources said.
In an application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, the Director, Government and Regulatory Affairs at Serum Institute of India (SII) cited that the UK’s Medicines and Healthcare products Regulatory Agency has already approved the booster dose of AstraZeneca ChAdOx1 nCoV-19 vaccine, they said.
Recently, Kerala, Rajasthan, Karnataka and Chhattisgarh have urged the Centre to decide on allowing booster doses of Covid-19 vaccine diseased amid concerns raised by ‘Omicron’, the new variant of SARS-CoV-2.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More

Eating junk food linked with reduced deep sleep quality: Study

Serum Institute writes to govt, seeks in-house testing of its injection for detection of latent TB

Hypertension due to high salt intake linked with emotional, cognitive dysfunction

Delay in seeking treatment key reason behind deaths due to acute cardiac events: Study

Discovering the joy of baking: Nitte Institute of Hospitality Services organizes kids cooking camp
MUST WATCH
Latest Additions

Technology is radically changing sleep as we know it

Deccan Queen completes 93 years of service, rail enthusiasts cut cake at Pune station to celebrate train’s birthday

Australia head into the WTC final against India wary of their dismal Oval record

India’s manufacturing PMI hits 31-month high in May on substantial improvement in operating conditions

Drone strikes hit Moscow and Kyiv – in the growing world of drone warfare, anything goes when it comes to international law